By 1995, Stoppa-Lyonnet could offer her patients a test that identifies brca1 mutations and calculates a woman's predisposition to the disease. Enter the European Patent Office, which in January 2001 granted the American biotechnology company Myriad Genetics a Europe-wide...
To continue reading:
or
Log-In